Several phosphoinositide 3-kinase(PI3 K) inhibitors are currently approved to treat hematolymphatic malignant diseases worldwide, and many drugs that have the same target are in the clinical research stage. In March 2...Several phosphoinositide 3-kinase(PI3 K) inhibitors are currently approved to treat hematolymphatic malignant diseases worldwide, and many drugs that have the same target are in the clinical research stage. In March 2022,duvelisib became the first PI3 K inhibitor approved in China indicated for the treatment of hematolymphatic malignant diseases. Meanwhile, linperlisib and copanlisib have almost completed the technical review of the clinical specialty. The Center for Drug Evaluation(CDE) of the China National Medical Products Administration(NMPA) found that class I PI3 K inhibitors can cause various degrees of immune-related adverse events, which are associated with action mechanisms, affecting the benefit-risk assessment of the drugs. On April 21, 2021, the United States Food and Drug Administration(FDA) convened the Oncologic Drugs Advisory Committee(ODAC)meeting to discuss the safety of PI3 K inhibitors indicated for hematolymphatic malignancies and their related risk of death. The hematological tumor group of CDE of the China NMPA summarized and combined the data on PI3 K inhibitors listed or under technical review for marketing authorization applications and found that such products may have unique efficacy and safety characteristics in Chinese patients with malignant lymphoma.展开更多
目的探讨PI3K抑制剂林普利塞(Linperlisib,YY-20394)对弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)的抗肿瘤效应及其作用机制。方法采用CCK-8法检测不同浓度YY-20394对SU-DHL-4细胞(GCB亚型)和U2932细胞(ABC亚型)增殖能力...目的探讨PI3K抑制剂林普利塞(Linperlisib,YY-20394)对弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)的抗肿瘤效应及其作用机制。方法采用CCK-8法检测不同浓度YY-20394对SU-DHL-4细胞(GCB亚型)和U2932细胞(ABC亚型)增殖能力的影响,并计算出24 h时药物的IC_(25)、IC_(50)、IC_(75)。采用流式细胞术检测IC_(25)、IC_(50)和IC_(75)浓度YY-20394对SU-DHL-4细胞和U2932细胞凋亡的影响。采用高通量RNA测序技术(RNA-Seq)检测药物作用前后各组细胞基因表达的变化,对差异表达基因进行KEGG信号通路分析和GO富集分析,并且对各组细胞基因表达数据进行GSEA富集分析。结果在YY-20394作用下,SU-DHL-4细胞增殖抑制率和细胞凋亡率增加(P<0.05),但U2932细胞增殖及凋亡能力未发生明显改变(P>0.05)。KEGG和GO富集分析结果显示,YY-20394对SU-DHL-4细胞的抗肿瘤作用涉及多条信号通路,其中PI3K-AKT、MAPK、JAK-STAT等信号通路的活性下调,且可能通过影响醇类物质合成等细胞生物学功能发挥作用;而U2932细胞中未富集到具有显著差异的信号通路。GSEA富集分析显示PI3K-AKT信号通路在SU-DHL-4细胞中的活化水平显著低于U2932细胞。结论PI3K抑制剂YY-20394通过影响PI3K-AKT等肿瘤相关信号通路,对GCB亚型的SU-DHL-4细胞产生抗肿瘤效应,而对ABC亚型的U2932细胞不敏感。展开更多
目的探讨LED光源照射对人视网膜色素上皮(RPE)细胞自噬和凋亡的影响,以及磷脂酰肌醇3激酶(PI3K)抑制剂LY294002在光照下对RPE细胞自噬和凋亡的影响。方法体外培养人ARPE-19细胞,随机分为6 h对照组、6 h模型组、6 h LY294002组,12 h对照...目的探讨LED光源照射对人视网膜色素上皮(RPE)细胞自噬和凋亡的影响,以及磷脂酰肌醇3激酶(PI3K)抑制剂LY294002在光照下对RPE细胞自噬和凋亡的影响。方法体外培养人ARPE-19细胞,随机分为6 h对照组、6 h模型组、6 h LY294002组,12 h对照组、12 h模型组、12 h LY294002组,24 h对照组、24 h模型组、24 h LY294002组,分别给于设定时间的LED冷光照射或加入LY294002后的光照。采用噻唑蓝法检测各组细胞存活率;流式细胞术检测各组细胞凋亡率;透射电子显微镜观察各组细胞超微结构;构建稳定表达红色荧光蛋白-绿色荧光蛋白-微管相关蛋白1轻链3(LC3)的RPE细胞株,激光共聚焦合倒置荧光显微镜分析细胞自噬流变化;Western blot法检测苄氯素1(Beclin 1)、LC3和p62自噬相关蛋白表达水平。结果与对照组比较,6、12、24 h模型组细胞存活率均下降(均P<0.05),12、24 h LY294002组细胞存活率均下降(均P<0.01);与模型组比较,12、24 h LY294002组细胞存活率均升高(均P<0.05)。与对照组比较,6、12、24 h模型组和LY294002组细胞凋亡率均升高(均P<0.05);与模型组比较,6、12 h LY294002组细胞凋亡率均下降(均P<0.05)。模型组RPE细胞在光照24 h后,胞内可见较多的自噬泡,LY294002干预后也可见聚集性分布的自噬囊泡。观察自噬流发现,对照组少见红色亮点,模型组红色亮点荧光随光照时间延长数量逐渐增多,Merge图中黄色亮点数量增多明显,LY294002干预后,红色亮点与黄色亮点呈增多趋势。与对照组比较,6、12、24 h模型组和LY294002组细胞中Beclin 1、LC3Ⅱ/LC3Ⅰ蛋白表达水平均升高,p62蛋白表达水平均下降,差异均有统计学意义(均P<0.05);与模型组比较,6、12、24 h LY294002组细胞中Beclin 1、LC3Ⅱ/LC3Ⅰ蛋白表达均升高,12、24 h LY294002组细胞中p62蛋白表达水平均下降,差异均有统计学意义(均P<0.05)。结论LED光源照射可刺激ARPE-19细胞发生自噬,增加细胞凋亡率;PI3K抑制剂LY294002能上调细胞的自噬活性,减缓凋亡。展开更多
Glioblastoma is carcinogenesis of glial cells in central nervous system and has the highest incidence among primary brain tumors.Brain metastasis,such as breast cancer and lung cancer,also leads to high mortality.The ...Glioblastoma is carcinogenesis of glial cells in central nervous system and has the highest incidence among primary brain tumors.Brain metastasis,such as breast cancer and lung cancer,also leads to high mortality.The available medicines are limited due to blood-brain barrier.Abnormal activation of phosphatidylinositol 3-kinases(PI3 K)signaling pathway is prevalent in glioblastoma and metastatic tumors.Here,we characterized a 2-amino-4-methylquinazoline derivative XH30 as a potent PI3 K inhibitor with excellent anti-tumor activity against human glioblastoma.XH30 significantly repressed the proliferation of various brain cancer cells and decreased the phosphorylation of key proteins of PI3 K signaling pathway,induced cell cycle arrest in G1 phase as well.Additionally,XH30 inhibited the migration of glioma cells and blocked the activation of PI3 K pathway by interleukin-17 A(IL-17 A),which increased the migration of U87 MG.Oral administration of XH30 significantly suppressed the tumor growth in both subcutaneous and orthotopic tumor models.XH30 also repressed tumor growth in brain metastasis models of lung cancers.Moreover,XH30 reduced IL-17 A and its receptor IL-17 RA in vivo.These results indicate that XH30 might be a potential therapeutic drug candidate for glioblastoma migration and brain metastasis.展开更多
Since the PI3K signaling pathway is the most commonly activated in human cancers,inhibition of PI3K is a promising approach to cancer therapy.In this study,a series of 2-methyl-5-nitrobenzeneacylhydrazones were design...Since the PI3K signaling pathway is the most commonly activated in human cancers,inhibition of PI3K is a promising approach to cancer therapy.In this study,a series of 2-methyl-5-nitrobenzeneacylhydrazones were designed and synthesized.All the new derivatives were tested by p110α enzymatic and Rh30 cellular assays.Further enzyme selectivity profiling proved that 6e and 7 were potential selective PI3K inhibitors.展开更多
文摘Several phosphoinositide 3-kinase(PI3 K) inhibitors are currently approved to treat hematolymphatic malignant diseases worldwide, and many drugs that have the same target are in the clinical research stage. In March 2022,duvelisib became the first PI3 K inhibitor approved in China indicated for the treatment of hematolymphatic malignant diseases. Meanwhile, linperlisib and copanlisib have almost completed the technical review of the clinical specialty. The Center for Drug Evaluation(CDE) of the China National Medical Products Administration(NMPA) found that class I PI3 K inhibitors can cause various degrees of immune-related adverse events, which are associated with action mechanisms, affecting the benefit-risk assessment of the drugs. On April 21, 2021, the United States Food and Drug Administration(FDA) convened the Oncologic Drugs Advisory Committee(ODAC)meeting to discuss the safety of PI3 K inhibitors indicated for hematolymphatic malignancies and their related risk of death. The hematological tumor group of CDE of the China NMPA summarized and combined the data on PI3 K inhibitors listed or under technical review for marketing authorization applications and found that such products may have unique efficacy and safety characteristics in Chinese patients with malignant lymphoma.
文摘目的探讨PI3K抑制剂林普利塞(Linperlisib,YY-20394)对弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)的抗肿瘤效应及其作用机制。方法采用CCK-8法检测不同浓度YY-20394对SU-DHL-4细胞(GCB亚型)和U2932细胞(ABC亚型)增殖能力的影响,并计算出24 h时药物的IC_(25)、IC_(50)、IC_(75)。采用流式细胞术检测IC_(25)、IC_(50)和IC_(75)浓度YY-20394对SU-DHL-4细胞和U2932细胞凋亡的影响。采用高通量RNA测序技术(RNA-Seq)检测药物作用前后各组细胞基因表达的变化,对差异表达基因进行KEGG信号通路分析和GO富集分析,并且对各组细胞基因表达数据进行GSEA富集分析。结果在YY-20394作用下,SU-DHL-4细胞增殖抑制率和细胞凋亡率增加(P<0.05),但U2932细胞增殖及凋亡能力未发生明显改变(P>0.05)。KEGG和GO富集分析结果显示,YY-20394对SU-DHL-4细胞的抗肿瘤作用涉及多条信号通路,其中PI3K-AKT、MAPK、JAK-STAT等信号通路的活性下调,且可能通过影响醇类物质合成等细胞生物学功能发挥作用;而U2932细胞中未富集到具有显著差异的信号通路。GSEA富集分析显示PI3K-AKT信号通路在SU-DHL-4细胞中的活化水平显著低于U2932细胞。结论PI3K抑制剂YY-20394通过影响PI3K-AKT等肿瘤相关信号通路,对GCB亚型的SU-DHL-4细胞产生抗肿瘤效应,而对ABC亚型的U2932细胞不敏感。
文摘目的探讨LED光源照射对人视网膜色素上皮(RPE)细胞自噬和凋亡的影响,以及磷脂酰肌醇3激酶(PI3K)抑制剂LY294002在光照下对RPE细胞自噬和凋亡的影响。方法体外培养人ARPE-19细胞,随机分为6 h对照组、6 h模型组、6 h LY294002组,12 h对照组、12 h模型组、12 h LY294002组,24 h对照组、24 h模型组、24 h LY294002组,分别给于设定时间的LED冷光照射或加入LY294002后的光照。采用噻唑蓝法检测各组细胞存活率;流式细胞术检测各组细胞凋亡率;透射电子显微镜观察各组细胞超微结构;构建稳定表达红色荧光蛋白-绿色荧光蛋白-微管相关蛋白1轻链3(LC3)的RPE细胞株,激光共聚焦合倒置荧光显微镜分析细胞自噬流变化;Western blot法检测苄氯素1(Beclin 1)、LC3和p62自噬相关蛋白表达水平。结果与对照组比较,6、12、24 h模型组细胞存活率均下降(均P<0.05),12、24 h LY294002组细胞存活率均下降(均P<0.01);与模型组比较,12、24 h LY294002组细胞存活率均升高(均P<0.05)。与对照组比较,6、12、24 h模型组和LY294002组细胞凋亡率均升高(均P<0.05);与模型组比较,6、12 h LY294002组细胞凋亡率均下降(均P<0.05)。模型组RPE细胞在光照24 h后,胞内可见较多的自噬泡,LY294002干预后也可见聚集性分布的自噬囊泡。观察自噬流发现,对照组少见红色亮点,模型组红色亮点荧光随光照时间延长数量逐渐增多,Merge图中黄色亮点数量增多明显,LY294002干预后,红色亮点与黄色亮点呈增多趋势。与对照组比较,6、12、24 h模型组和LY294002组细胞中Beclin 1、LC3Ⅱ/LC3Ⅰ蛋白表达水平均升高,p62蛋白表达水平均下降,差异均有统计学意义(均P<0.05);与模型组比较,6、12、24 h LY294002组细胞中Beclin 1、LC3Ⅱ/LC3Ⅰ蛋白表达均升高,12、24 h LY294002组细胞中p62蛋白表达水平均下降,差异均有统计学意义(均P<0.05)。结论LED光源照射可刺激ARPE-19细胞发生自噬,增加细胞凋亡率;PI3K抑制剂LY294002能上调细胞的自噬活性,减缓凋亡。
基金supported by the CAMS Innovation Fund(2016I2M-3-008,China)The Drug Innovation Major Project(2018ZX09711001-003-011 and 2018ZX09711001-005-017,China)the Non-Profit Central Research Institute Fund of Chinese Academy of Medical Sciences(Grant 2018PT35003,China)。
文摘Glioblastoma is carcinogenesis of glial cells in central nervous system and has the highest incidence among primary brain tumors.Brain metastasis,such as breast cancer and lung cancer,also leads to high mortality.The available medicines are limited due to blood-brain barrier.Abnormal activation of phosphatidylinositol 3-kinases(PI3 K)signaling pathway is prevalent in glioblastoma and metastatic tumors.Here,we characterized a 2-amino-4-methylquinazoline derivative XH30 as a potent PI3 K inhibitor with excellent anti-tumor activity against human glioblastoma.XH30 significantly repressed the proliferation of various brain cancer cells and decreased the phosphorylation of key proteins of PI3 K signaling pathway,induced cell cycle arrest in G1 phase as well.Additionally,XH30 inhibited the migration of glioma cells and blocked the activation of PI3 K pathway by interleukin-17 A(IL-17 A),which increased the migration of U87 MG.Oral administration of XH30 significantly suppressed the tumor growth in both subcutaneous and orthotopic tumor models.XH30 also repressed tumor growth in brain metastasis models of lung cancers.Moreover,XH30 reduced IL-17 A and its receptor IL-17 RA in vivo.These results indicate that XH30 might be a potential therapeutic drug candidate for glioblastoma migration and brain metastasis.
基金the National Natural Science Foundation of China(Nos.81273365 and 81321092)Chinese National Science&Technology Major Project "Key New Drug Creation and Manufacturing Program"(Nos.2012ZX09103101-024 and 2014ZX09304002-008-001)+1 种基金Chinese National Programs for High Technology Research and Development(No.2012AA020302)the Shanghai Science and Technology Commission(Nos.11431921100 and 12DZ1930802)for their financial support
文摘Since the PI3K signaling pathway is the most commonly activated in human cancers,inhibition of PI3K is a promising approach to cancer therapy.In this study,a series of 2-methyl-5-nitrobenzeneacylhydrazones were designed and synthesized.All the new derivatives were tested by p110α enzymatic and Rh30 cellular assays.Further enzyme selectivity profiling proved that 6e and 7 were potential selective PI3K inhibitors.
